Drug Trial Radar · NCT06049342
A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 25, 2024
Primary completion
Jun 2024
Study completion May 2025
Sponsor
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai 6th People's Hospital; Beijing Luhe Hospital
- First posted
- Sep 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.
Conditions
- Knee Osteoarthritis
Interventions
NCR100 injectionBiological
Subjects will receive a one-dose intra-articular NCR100 injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event(AE) or Serious Adverse Event(SAE)Time frame: Week1,Week2,Week4
- Dose-Limiting Toxicity(DLT)Time frame: 4 weeks after injection
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.